Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748287 · ClinicalTrials.gov registry record · Early Phase 1
A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 104
- Enrollment target
NCT06748287: Completed Early Phase 1 study, sponsored by University of Minnesota.
NCT06748287 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 104 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06748287, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
Photobiomodulation is a form of non-ionizing light therapy has been shown to stimulate cellular processes and reduce inflammation as well as improve pain and wound healing. Photobiomodulation has also been found to enhance fibroblast growth factor production. A challenge in clinic is to answer the patients' questions regarding which FDA-cleared device is the best to purchase. Therefore, this study was designed to gain experience with the use of the following devices and to clinically evaluate their efficacy: iGrow Hair Growth System, Capillus352, Hair Max Ultima 12 LaserComb, and HairMax Laserband 82. The purpose of this pilot research study is to clinically compare and evaluate FDA-cleared photobiomodulation devices after four months of treatment and one-month follow-up in subjects with alopecia.
Primary Outcome
Units on a scale. Standardized rating system used in research to assess various dermatologic conditions, including hair loss (-3-+3). It involves visual examination by trained board-certified dermatologists to evaluate specific criteria assessing the overall severity of hair loss.
Interventions
- DEVICE iGrow Hair Growth System
- DEVICE Capillus352
- DEVICE HairMax Ultima 12 Lasercomb
- DEVICE HairMax Laserband 82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2023-02-01 |
| Phase | Early Phase 1 |
What the finished NCT06748287 record still lists
NCT06748287 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 4 interventions - of which iGrow Hair Growth System is the first listed.
NCT06748287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06748287 about?
NCT06748287 is a clinical study titled "A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia". Photobiomodulation is a form of non-ionizing light therapy has been shown to stimulate cellular processes and reduce inflammation as well as improve pain and wound healing. Photobiomodulation has also been found to enhance fibroblast growth factor production. A challenge in clinic is to answer the p...
What is the current status of trial NCT06748287?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 104 participants. The study started on 2017-01-03. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT06748287?
The interventions under investigation include: iGrow Hair Growth System (DEVICE), Capillus352 (DEVICE), HairMax Ultima 12 Lasercomb (DEVICE), HairMax Laserband 82 (DEVICE).
Who is sponsoring clinical trial NCT06748287?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06748287's enrollment target sits among peer trials
104 176th of 2000 higher than 1,821 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI